Payment overview · 2025
General Payments
$131.63
6 reported records · 6 companies
Healthcare provider profile · identity verified
Galina Kletsman, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1528003019
Verified facts
What the public records show
CMS Open Payments records show Galina Kletsman, D.O. received $131.63 in general payments during 2025 across 6 reported records.
Ardelyx, Inc. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Zenpep by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Edarbyclor by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.00 | 22.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.40 | 17.0% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $22.09 | 16.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.71 | 15.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.57 | 14.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.86 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.63 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
103 | 26 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 585 | 125 |
| Losartan Potassium | Losartan Potassium | 402 | 97 |
| Omeprazole | Omeprazole | 319 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 55 |
| Linzess | Linaclotide | 241 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 239 | 50 |
| Metformin Hcl | Metformin Hcl | 204 | 43 |
| Famotidine | Famotidine | 185 | 50 |
| Synthroid | Levothyroxine Sodium | 182 | 41 |
| Vascepa | Icosapent Ethyl | 171 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 170 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 168 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 39 |
| Carvedilol | Carvedilol | 150 | 30 |
| Glipizide Er | Glipizide | 139 | 25 |
| Meloxicam | Meloxicam | 137 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 31 |
| Simvastatin | Simvastatin | 128 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 121 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 28 |
| Mirtazapine | Mirtazapine | 109 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 108 | 22 |
| Zenpep | Lipase/Protease/Amylase | 103 | 26 |
| Furosemide | Furosemide | 102 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 19 |
| Creon | Lipase/Protease/Amylase | 100 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 23 |
| Eliquis | Apixaban | 93 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 51 |
| Repaglinide | Repaglinide | 87 | 21 |
| Ezetimibe | Ezetimibe | 80 | 18 |
| Nitroglycerin Patch | Nitroglycerin | 77 | 23 |
| Telmisartan | Telmisartan | 75 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 21 |
| Glimepiride | Glimepiride | 69 | 15 |
| Januvia | Sitagliptin Phosphate | 69 | 16 |
| Myrbetriq | Mirabegron | 68 | 14 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Ketoconazole | Ketoconazole | 64 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | suppressed |
| Atenolol | Atenolol | 61 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 60 | 16 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 59 | 14 |
| Gabapentin | Gabapentin | 59 | 15 |
| Clonidine Hcl | Clonidine Hcl | 57 | 32 |
| Ibuprofen | Ibuprofen | 57 | 32 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Propranolol Hcl | Propranolol Hcl | 55 | 17 |
| Allopurinol | Allopurinol | 52 | 12 |
| Mupirocin | Mupirocin | 51 | 20 |
| Nifedipine Er | Nifedipine | 51 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 17 |
| Nystatin | Nystatin | 49 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Febuxostat | Febuxostat | 45 | suppressed |
| Proctozone-Hc | Hydrocortisone | 45 | 14 |
| Colchicine | Colchicine | 41 | 13 |
| Finasteride | Finasteride | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 16 |
| Ramipril | Ramipril | 41 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 16 |
| Valsartan | Valsartan | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 33 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Fluocinonide | Fluocinonide | 36 | 21 |
| Ozempic | Semaglutide | 35 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 13 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Felodipine Er | Felodipine | 27 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 26 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 23 |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Baclofen | Baclofen | 20 | 12 |
| Cephalexin | Cephalexin | 20 | 20 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | 11 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | 11 |
| Gemtesa | Vibegron | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.63 · 6 records | Ardelyx, Inc. | EDARBI, ELIQUIS, IBSRELA, NURTEC ODT, Topical Oxygen Chamber for extremities, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error